35 results found.

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Osteonecrosis, Acute Lymphoblastic Leukaemia, or Lymphoblastic Ly Clinical Trial

Heinrich-Heine University, Duesseldorf - Recruiting 10 years to 18 years.
- Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL.

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphob Clinical Trial using Clofarabine; Mitoxantrone

New York Medical College - Recruiting N/A to 30 years.
- A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
Clofarabine; Mitoxantrone

Lymphoblastic Leukemia, Acute T-cell, or Precursor T-Cell Lymphob Clinical Trial using BMS-906024; Dexamethasone

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
BMS-906024; Dexamethasone

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Clinical Trial using plerixafor; filgrastim; etoposide; leukapheresis

Case Comprehensive Cancer Center - Recruiting 18 years to 78 years.
- A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma.
plerixafor; filgrastim; etoposide; leukapheresis

B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Diffuse Clinical Trial using rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Children's Oncology Group - Recruiting N/A to 18 years.
- Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Relapsed Lymphoblastic Leukemia, Relapsed Lymphoblastic Lymphoma, Clinical Trial using Sirolimus

Children's Hospital Medical Center, Cincinnati - Recruiting N/A to 30 years.
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Sirolimus

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, or Lymp Clinical Trial using BPX-501 and AP1903

Bellicum Pharmaceuticals - Recruiting 18 years to 65 years.
- A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant).
BPX-501 and AP1903

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Acute Lymphocytic Leukemia, or Adult Lymphoblastic Lymphoma Clinical Trial using DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

University of California, San Diego - Recruiting 18 years to 60 years.
- A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocytr) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Diffuse Clinical Trial using doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute L Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History.

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Lymphoblastic Leukemia, or Lymphoblastic Lymphoma Clinical Trial using Daunorubicin; Vincristine; PEG-asparaginase; Intrathecal Methotrexate; Cyclophosphamide; Cytarabine; Mercaptopurine; Methotrexate; Doxorubicin; Thioguanine

M.D. Anderson Cancer Center - Recruiting 12 years to 40 years.
- Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.
Daunorubicin; Vincristine; PEG-asparaginase; Intrathecal Methotrexate; Cyclophosphamide; Cytarabine; Mercaptopurine; Methotrexate; Doxorubicin; Thioguanine

Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplan Clinical Trial using Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant

M.D. Anderson Cancer Center - Recruiting N/A to 65 years.
- Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia.
Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant

Leukemia, Acute Lymphoblastic, Precursor B-Cell Lymphoblastic Leu Clinical Trial using Diagnosed as ALL

Asan Medical Center - Recruiting 15 years or older.
- Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center.
Diagnosed as ALL

Leukaemia, Lymphoblastic, Acute Clinical Trial using nelarabine

GlaxoSmithKline - Recruiting N/A to 21 years.
- A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma.
nelarabine

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma Clinical Trial using CAT-8015 (Moxetumomab Pasudotox)

MedImmune LLC - Recruiting 6 Months to 25 years.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL).
CAT-8015 (Moxetumomab Pasudotox)

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous S Clinical Trial using doxorubicin hydrochloride; cytarabine; daunorubicin hydrochloride; prednisone; pegaspargase; methotrexate; leucovorin calcium; cyclophosphamide; mercaptopurine; nelarabine; asparaginase; dexamethasone; thioguanine; vincristine sulfate; radiation therapy; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 1 year to 30 years.
- Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma.
doxorubicin hydrochloride; cytarabine; daunorubicin hydrochloride; prednisone; pegaspargase; methotrexate; leucovorin calcium; cyclophosphamide; mercaptopurine; nelarabine; asparaginase; dexamethasone; thioguanine; vincristine sulfate; radiation therapy; laboratory biomarker analysis

Precursor Cell Lymphoblastic Leukemia-Lymphoma Clinical Trial using G-CSF; Ifosfamide; Etoposide; Dexamethasone; Mesna

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia.
G-CSF; Ifosfamide; Etoposide; Dexamethasone; Mesna

Precursor Cell Lymphoblastic Leukemia-Lymphoma Clinical Trial using Rituximab+mVPDL

Asan Medical Center - Recruiting 15 years or older.
- Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Philadelphia-Negative Adult Acute Lymphoblastic Leukemia.
Rituximab+mVPDL

Leukemia, or Lymphoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.
biologic sample preservation procedure

Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, or Non- Clinical Trial using Fenretinide; Cytarabine; Methotrexate

South Plains Oncology Consortium - Recruiting N/A to 21 years.
- A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058'.
Fenretinide; Cytarabine; Methotrexate

Burkitt Lymphoma, or B-Cell Acute Lymphoblastic Leukemia Clinical Trial using Chemotherapy-Rituximab combination

Northern Italy Leukemia Group - Recruiting 15 years or older.
- Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma.
Chemotherapy-Rituximab combination

Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma Clinical Trial using Rituximab

University of Bologna - Recruiting 18 years or older.
- Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults.
Rituximab